Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breakpoints: current practice and future perspectives.

Johan W Mouton1

  • 1Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 sz, Nijmegen, The Netherlands. mouton@cwz.nl

International Journal of Antimicrobial Agents
|April 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications.

The Journal of antimicrobial chemotherapy·2022
Same author

Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance.

The Journal of antimicrobial chemotherapy·2022
Same author

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2021
Same author

Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.

The Journal of antimicrobial chemotherapy·2021
Same author

The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis.

Open forum infectious diseases·2021
Same author

Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.

BMC infectious diseases·2021
Same journal

Machine Learning-Based Drug Susceptibility Prediction from Candida Genomic Data.

International journal of antimicrobial agents·2026
Same journal

Vancomycin Penetration into Intra-abdominal Compartments: Site Concentration Disparities and Implications for Dose Optimization in Gram-Positive Infections.

International journal of antimicrobial agents·2026
Same journal

Strain-dependent variability in pharmacodynamic interactions for phage-antibiotic combinations in Pseudomonas aeruginosa.

International journal of antimicrobial agents·2026
Same journal

Carbapenem-resistant Enterobacterales across the UK: a nationwide study of carbapenemase testing and novel antimicrobial activity.

International journal of antimicrobial agents·2026
Same journal

Kidney Injury, Dialysis, and Mortality with Vancomycin Plus Piperacillin-Tazobactam or Cefepime.

International journal of antimicrobial agents·2026
Same journal

Ceftaroline pharmacokinetics on ECMO, a pediatric case report.

International journal of antimicrobial agents·2026
See all related articles

This study highlights the critical difference between clinical and microbiological breakpoints for antimicrobial resistance. Differentiating these breakpoints is essential for accurate clinical decisions and monitoring emerging resistance patterns.

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmacology and Therapeutics
  • Clinical Diagnostics

Background:

  • Historically, breakpoints have served dual roles: predicting clinical success and detecting resistant microbial populations.
  • This dual usage has led to divergent approaches in setting and interpreting breakpoints for clinical efficacy versus resistance detection.
  • Current guidelines often fail to distinguish between these two distinct meanings of breakpoints.

Purpose of the Study:

  • To advocate for the clear differentiation between clinical and microbiological breakpoints.
  • To underscore the distinct applications and interpretations required for each type of breakpoint.
  • To propose enhanced reporting methods for clinical breakpoints.

Main Methods:

  • Discussion and analysis of existing breakpoint methodologies and guidelines.

Related Experiment Videos

  • Review of methods for establishing meaningful clinical breakpoints, including CART analysis.
  • Exploration of advanced techniques like Monte Carlo simulations for breakpoint determination.

    • Main Results:

    • Clinical breakpoints (Susceptible, Intermediate, Resistant) are crucial for guiding treatment decisions and correlating with clinical outcomes.
    • Microbiological breakpoints are valuable for detecting non-native resistant organisms and monitoring the emergence of resistant subpopulations.
    • Current reporting practices for breakpoints lack sufficient detail for comprehensive clinical interpretation.

    Conclusions:

    • Recognizing the difference between clinical and microbiological breakpoints is essential for effective antimicrobial stewardship.
    • Future reports should supplement S, I, R classifications with measured Minimum Inhibitory Concentrations (MICs).
    • Integrating population pharmacokinetics and MIC distributions with methods like Monte Carlo simulation can improve predictions of treatment success.